Morgan Stanley analyst Sarita Kapila maintained a Buy rating on AstraZeneca today and set a price target of p15,500.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sarita Kapila’s rating is based on AstraZeneca’s strong position within the pharmaceutical sector, which is expected to experience significant growth. The company is highlighted as a top pick due to its sector-leading earnings growth and a promising pipeline that suggests potential for further earnings upside.
Additionally, the broader sector fundamentals appear robust, with major overhangs such as tariffs and US pricing risks largely resolved. This creates a favorable environment for AstraZeneca to capitalize on growth opportunities, particularly in areas like obesity, breast cancer, and ATTR-CM, which are expected to be key themes shaping the equity story into 2026.
Kapila covers the Healthcare sector, focusing on stocks such as GlaxoSmithKline, UCB SA, and AstraZeneca. According to TipRanks, Kapila has an average return of -1.6% and a 52.38% success rate on recommended stocks.
In another report released on December 1, Jefferies also maintained a Buy rating on the stock with a £150.00 price target.